1. 302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors. (September 2015) Authors: Italiano, A.; Keilhack, H.; Toulmonde, M.; Coindre, J.M.; Michot, J.M.; Massard, C.; Ottesen, L.; Reyderman, L.; Blakemore, S.J.; Kraljevic, S.; Thomson, B.; McDonald, A.; Ho, P.T.; Ribrag, V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. (June 2017) Authors: Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M.J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. (June 2017) Authors: Blakemore, S.J.; Daigle, S.R.; McDonald, A.A.; Morschhauser, F.; Ribrag, V.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Le Gouill, S.; Fruchart, C.; Radford, J.; Zinzani, P.L.; Assouline, S.; Cartron, G.; Dickinson, M.; Morin, R.; Wu, H.; Sausen, M.; Clawson, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗